

Product Pipeline

Candidate	Target	Description	Indication(s)	Preclin	Phase 1	Phase 2	Phase 3
Rindopepimut*	EGFR variant III	vaccine	Front-line glioblastoma	ACT IV Registration Trial			
Rindopepimut*	EGFR variant III	vaccine	Recurrent glioblastoma	ReACT Trial			
CDX-011**	GPNMB	ADC	Breast cancer	EMERGE Trial			
CDX-1401	NY-ESO-1	mAb-vaccine	Multiple solid tumors				
CDX-1127	CD27	mAb	Lymphoma/leukemia and solid tumors				
CDX-301	FLT3 ligand	protein	HSC transplantation				
CDX-1135***	Soluble CR1	protein	Renal disease				
CDX-014	TIM-1	ADC/mAb	Ovarian and renal cancers				

* Rindopepimut: formerly CDX-110

** CDX-011: glembatumumab vedotin (ADC technology licensed from Seattle Genetics)

*** CDX-1135: has completed safety studies in other indications